iBio, Inc. (IBIO) News

iBio, Inc. (IBIO): $0.31

0.00 (0.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IBIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 422

in industry

Filter IBIO News Items

IBIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IBIO News Highlights

  • For IBIO, its 30 day story count is now at 10.
  • Over the past 19 days, the trend for IBIO's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • The most mentioned tickers in articles about IBIO are DRUG.

Latest IBIO News From Around the Web

Below are the latest news stories about iBio Inc that investors may wish to consider to help them evaluate IBIO as an investment opportunity.

iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announces its financial results for the fiscal quarter ended December 31, 2021 and provides a corporate update. “We are pleased to report that we have now added six new immuno-oncology assets to our pipeline in the six months since we announced our new drug discovery capabiliti

Yahoo | February 14, 2022

iBio Q2 2022 Earnings Preview

iBio (NYSE:IBIO) is scheduled to announce Q2 earnings results on Monday, February 14th, after market close. The consensus EPS Estimate is -$0.04 (flat Y/Y) and the consensus Revenue Estimate is $0.25M (-64.8% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue estimates...

Seeking Alpha | February 13, 2022

iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022

BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 second quarter financial results after market close on Monday, February 14, 2022. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Yahoo | February 7, 2022

iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease

iBio Inc (NYSE: IBIO ) received the FDA response to its pre-investigational new drug (IND) package for IBIO-202, the Company''s lead COVID-19 vaccine program. In light of the feedback received, the Company is moving forward with IND-enabling challenge studies for its second-generation … Full story available on Benzinga.com

Benzinga | January 26, 2022

iBio provides update on COVID-19 vaccine program IBIO-202

iBio <> provided an update on its lead COVID-19 vaccine program IBIO-202. The company said that according to feedback received from the U.S

Seeking Alpha | January 26, 2022

iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease

- IBIO-202 Designed to Address Unmet Needs for Durability, Access, and Variant-inclusion -BRYAN, Texas, Jan. 26, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today shared an update on its lead COVID-19 vaccine program, IBIO-202. iBio recently received the U.S. Food and Drug Administration’s (“FDA”) response to its pre-investigational new drug (“IND”)

Yahoo | January 26, 2022

Vaxart: Oral Covid-19 Vaccine Is Interesting, But Questions Linger

VXRT stock is more than a Covid-19 meme trade.

Ian Bezek on InvestorPlace | January 10, 2022

iBio Announces Participation in the H.C. Wainwright BioConnect Conference

BRYAN, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that it will participate in the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022. iBio's pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning on Monday, January 10, 2

Yahoo | January 4, 2022

iBio Inc. (IBIO) Rises From The Low: Could It Be A Catbird Seat?

iBio Inc. (AMEX:IBIO) concluded the trading at $0.66 on Wednesday, December 22 with a rise of 1.54% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $0.65 and 5Y monthly beta was reading -6.24 with its price kept floating in the range iBio Inc. (IBIO) Rises From The Low: Could It Be A Catbird Seat? Read More »

Stocks Register | December 23, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday!

William White on InvestorPlace | December 22, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6061 seconds.